Author

B. Al-Lazikani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

P. Workman· 3 shared A. A. Antolin· 2 shared P. A. Clarke· 2 shared A. De Haven Brandon· 1 shared A. Hayes· 1 shared C. Zhang· 1 shared F. Raynaud· 1 shared I. Collins· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

P. Workman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Evolution of kinase polypharmacology across HSP90 drug discovery

A. A. Antolin, P. A. Clarke, I. Collins, P. Workman, B. Al-Lazikani

This study systematically characterizes the kinase cross-pharmacology of HSP90 inhibitors and shows that polypharmacology evolved during drug optimization.

bioRxiv · Sep 9, 2020Pharmacology & Toxicology

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

C. Zhang, S. R. Stockwell, M. Elbanna, R. Ketteler, J. Freeman, B. Al-Lazikani, S. Eccles, A. De Haven Brandon, F. Raynaud, A. Hayes, P. A. Clarke, P. Workman, S. Mittnacht

This study shows that MET/FAK signaling can activate CDK2 independently of CDK4/6, leading to cell division, and suggests targeting MET/FAK could enhance CDK4/6 inhibitor therapies.

bioRxiv · Apr 8, 2019Cancer Biology

The off-target kinase landscape of clinical PARP inhibitors

A. A. Antolin, M. Ameratunga, U. Banerji, P. Clarke, P. Workman, B. Al-Lazikani

This study identifies the off-target kinase profiles of four FDA-approved PARP inhibitors, revealing unique polypharmacological effects with potential clinical implications.

bioRxiv · Jan 14, 2019Pharmacology & Toxicology